Please login to the form below

Not currently logged in

Government Accountability Office

This page shows the latest Government Accountability Office news and features for those working in and with pharma, biotech and healthcare.

Audit office says FDA 'is not meeting safety data obligations'

Audit office says FDA 'is not meeting safety data obligations'

Audit office says FDA 'is not meeting safety data obligations'. Criticised for not effectively tracking information about approved drugs. ... The Government Accountability Office (GAO) says in a new report that the regulator is meeting its objectives for

Latest news

  • PhRMA report shows increased R&D spend

    The trade group released the survey results the day after the Government Accountability Office (GAO) announced the results of a study showing that prescription drug spending in 2009 totalled around $250bn, ... of which $78bn - or about 31 per cent - was

  • FDA heparin crisis response criticised

    FDA heparin crisis response criticised. The Government Accountability Office has issued a report critical of the US FDA's management of the 2008 heparin contamination crisis. ... The Government Accountability Office (GAO) has issued a report that is

  • Most postmarketing trials on-track, FDA says

    In a study released late last year by the Government Accountability Office, the FDA was criticised for not keeping track of postmarketing commitments and failing to enforce the requirements sufficiently.

  • PhRMA names board nominees

    legislation. The trade group sent a letter to the Government Accountability Office nominating Pfizer chief medical officer Freda Lewis-Hall; Joshua J Ofman, Amgen's vice president of Global Coverage and ... Reimbursement, Global Government Affairs and

  • Calls for drug price investigation

    Leaders of two powerful Congressional committees in the US have asked the Government Accountability Office (GAO) to investigate prescription drug pricing trends and develop a proposal for an ongoing monitoring programme ... That deal promised to cut $8bn

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...